vs

Side-by-side financial comparison of ARGENX SE (ARGX) and Aramark (ARMK). Click either name above to swap in a different company.

Aramark is the larger business by last-quarter revenue ($4.8B vs $2.5B, roughly 2.0× ARGENX SE). ARGENX SE runs the higher net margin — 35.5% vs 2.0%, a 33.5% gap on every dollar of revenue. On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs 6.1%). ARGENX SE produced more free cash flow last quarter ($322.4M vs $-904.4M).

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.

Aramark is an American food service and facilities services provider to clients in areas including education, prisons, healthcare, business, and leisure. It operates in North America and an additional 14 countries, including the United Kingdom, Germany, Chile, Ireland, and Spain.

ARGX vs ARMK — Head-to-Head

Bigger by revenue
ARMK
ARMK
2.0× larger
ARMK
$4.8B
$2.5B
ARGX
Growing faster (revenue YoY)
ARGX
ARGX
+77.1% gap
ARGX
83.2%
6.1%
ARMK
Higher net margin
ARGX
ARGX
33.5% more per $
ARGX
35.5%
2.0%
ARMK
More free cash flow
ARGX
ARGX
$1.2B more FCF
ARGX
$322.4M
$-904.4M
ARMK

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ARGX
ARGX
ARMK
ARMK
Revenue
$2.5B
$4.8B
Net Profit
$877.2M
$96.2M
Gross Margin
89.5%
Operating Margin
28.9%
4.5%
Net Margin
35.5%
2.0%
Revenue YoY
83.2%
6.1%
Net Profit YoY
1.3%
-9.0%
EPS (diluted)
$13.25
$0.36

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARGX
ARGX
ARMK
ARMK
Q1 26
$4.8B
Q4 25
$2.5B
$5.0B
Q2 25
$1.8B
$4.6B
Q1 25
$4.3B
Q4 24
$1.4B
$4.6B
Q3 24
$4.4B
Q2 24
$901.9M
$4.4B
Q1 24
$4.2B
Net Profit
ARGX
ARGX
ARMK
ARMK
Q1 26
$96.2M
Q4 25
$877.2M
$87.1M
Q2 25
$414.8M
$71.8M
Q1 25
$61.9M
Q4 24
$865.6M
$105.6M
Q3 24
$122.4M
Q2 24
$-32.5M
$58.1M
Q1 24
$53.4M
Gross Margin
ARGX
ARGX
ARMK
ARMK
Q1 26
Q4 25
89.5%
Q2 25
89.2%
Q1 25
Q4 24
90.2%
Q3 24
Q2 24
89.4%
Q1 24
Operating Margin
ARGX
ARGX
ARMK
ARMK
Q1 26
4.5%
Q4 25
28.9%
4.3%
Q2 25
19.2%
3.9%
Q1 25
4.1%
Q4 24
8.7%
4.8%
Q3 24
5.0%
Q2 24
-15.4%
3.7%
Q1 24
3.8%
Net Margin
ARGX
ARGX
ARMK
ARMK
Q1 26
2.0%
Q4 25
35.5%
1.7%
Q2 25
23.4%
1.6%
Q1 25
1.4%
Q4 24
64.1%
2.3%
Q3 24
2.8%
Q2 24
-3.6%
1.3%
Q1 24
1.3%
EPS (diluted)
ARGX
ARGX
ARMK
ARMK
Q1 26
$0.36
Q4 25
$13.25
$0.33
Q2 25
$6.32
$0.27
Q1 25
$0.23
Q4 24
$13.33
$0.39
Q3 24
$0.46
Q2 24
$-0.55
$0.22
Q1 24
$0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARGX
ARGX
ARMK
ARMK
Cash + ST InvestmentsLiquidity on hand
$3.5B
$439.6M
Total DebtLower is stronger
$6.2B
Stockholders' EquityBook value
$7.3B
$3.2B
Total Assets
$8.7B
$13.5B
Debt / EquityLower = less leverage
1.94×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARGX
ARGX
ARMK
ARMK
Q1 26
$439.6M
Q4 25
$3.5B
$639.1M
Q2 25
$2.1B
$501.5M
Q1 25
$920.5M
Q4 24
$1.5B
$484.1M
Q3 24
$672.5M
Q2 24
$1.4B
$436.1M
Q1 24
$356.6M
Total Debt
ARGX
ARGX
ARMK
ARMK
Q1 26
$6.2B
Q4 25
$5.4B
Q2 25
$6.3B
Q1 25
$6.1B
Q4 24
$5.0B
Q3 24
$4.3B
Q2 24
$11.0M
$5.0B
Q1 24
$5.9B
Stockholders' Equity
ARGX
ARGX
ARMK
ARMK
Q1 26
$3.2B
Q4 25
$7.3B
$3.1B
Q2 25
$6.1B
$3.1B
Q1 25
$3.0B
Q4 24
$5.5B
$3.1B
Q3 24
$3.0B
Q2 24
$4.3B
$2.9B
Q1 24
$2.9B
Total Assets
ARGX
ARGX
ARMK
ARMK
Q1 26
$13.5B
Q4 25
$8.7B
$13.3B
Q2 25
$7.2B
$13.3B
Q1 25
$13.5B
Q4 24
$6.2B
$12.7B
Q3 24
$12.7B
Q2 24
$4.8B
$12.5B
Q1 24
$12.6B
Debt / Equity
ARGX
ARGX
ARMK
ARMK
Q1 26
1.94×
Q4 25
1.71×
Q2 25
2.03×
Q1 25
2.02×
Q4 24
1.61×
Q3 24
1.42×
Q2 24
0.00×
1.71×
Q1 24
2.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARGX
ARGX
ARMK
ARMK
Operating Cash FlowLast quarter
$323.3M
$-782.2M
Free Cash FlowOCF − Capex
$322.4M
$-904.4M
FCF MarginFCF / Revenue
13.0%
-18.7%
Capex IntensityCapex / Revenue
0.0%
2.5%
Cash ConversionOCF / Net Profit
0.37×
-8.13×
TTM Free Cash FlowTrailing 4 quarters
$594.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARGX
ARGX
ARMK
ARMK
Q1 26
$-782.2M
Q4 25
$323.3M
Q2 25
$361.8M
$76.7M
Q1 25
$255.9M
Q4 24
$41.9M
$-587.2M
Q3 24
$1.0B
Q2 24
$-124.7M
$140.7M
Q1 24
$221.3M
Free Cash Flow
ARGX
ARGX
ARMK
ARMK
Q1 26
$-904.4M
Q4 25
$322.4M
Q2 25
$356.6M
$-34.7M
Q1 25
$140.1M
Q4 24
$40.9M
$-707.0M
Q3 24
$882.3M
Q2 24
$-125.5M
$55.6M
Q1 24
$133.9M
FCF Margin
ARGX
ARGX
ARMK
ARMK
Q1 26
-18.7%
Q4 25
13.0%
Q2 25
20.1%
-0.8%
Q1 25
3.3%
Q4 24
3.0%
-15.5%
Q3 24
20.0%
Q2 24
-13.9%
1.3%
Q1 24
3.2%
Capex Intensity
ARGX
ARGX
ARMK
ARMK
Q1 26
2.5%
Q4 25
0.0%
2.8%
Q2 25
0.3%
2.4%
Q1 25
2.7%
Q4 24
0.1%
2.6%
Q3 24
3.2%
Q2 24
0.1%
1.9%
Q1 24
2.1%
Cash Conversion
ARGX
ARGX
ARMK
ARMK
Q1 26
-8.13×
Q4 25
0.37×
Q2 25
0.87×
1.07×
Q1 25
4.14×
Q4 24
0.05×
-5.56×
Q3 24
8.35×
Q2 24
2.42×
Q1 24
4.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARGX
ARGX

Segment breakdown not available.

ARMK
ARMK

Education$1.1B22%
Sports Leisure Corrections$961.2M20%
Food And Support Services International$847.8M18%
Other$621.6M13%
Businessand Industry$510.6M11%
Health Care$421.3M9%
Facility Services$382.9M8%

Related Comparisons